Clinical Trial

Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to better understand how safe and effective the drug cabozantinib in combination with high-dose ifosfamide is in the treatment of children and adults with relapsed/refractory sarcomas.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-11-24; most recent amendment 2025-11-12.
Trial Details
NCT Number NCT06156410
Lead Sponsor Children's Hospital of Philadelphia
Collaborators: Children's Hospital Colorado, Alex's Lemonade Stand Foundation, Exelixis
Conditions Ewing Sarcoma, Osteosarcoma, Sarcomas
Enrollment 30 participants
Start Date 2023-10-24
Primary Completion 2027-11 (estimated)
Study Completion 2028-11 (estimated)
Updated on ClinicalTrials.gov 2025-11-14